The Impact of Changes in Fasting Plasma Glucose Before and After Heart Failure Diagnosis on All-Cause Mortality.

IF 1.9 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiology Pub Date : 2025-05-30 DOI:10.1159/000546661

Boheng Zhang, Xiaokun Liu, Shouling Wu, Jing Yang, Qing Yue, Shuohua Chen, Quanle Han, Wei Wang, Qi Zhang

{"title":"The Impact of Changes in Fasting Plasma Glucose Before and After Heart Failure Diagnosis on All-Cause Mortality.","authors":"Boheng Zhang, Xiaokun Liu, Shouling Wu, Jing Yang, Qing Yue, Shuohua Chen, Quanle Han, Wei Wang, Qi Zhang","doi":"10.1159/000546661","DOIUrl":null,"url":null,"abstract":"Objective: This study evaluates the impact of fasting plasma glucose (FPG) changes before and after heart failure (HF) diagnosis on all-cause mortality, offering insights into personalized HF management strategies.Methods: A prospective cohort study based on the Kailuan study included 3533 Patients with HF after excluding those with prior HF, malignancies, or missing FPG data. FPG levels were measured before and after HF diagnosis and categorized into five groups: significant decrease (Q1), mild decrease (Q2), stable (Q3), mild increase (Q4), and significant increase (Q5). The primary endpoint was all-cause mortality, with follow-up until December 31, 2021.Results: Over a mean follow-up of 5.63±3.80 years, 1446 deaths occurred. Kaplan-Meier analysis showed increased mortality with larger FPG changes (P<0.0001). Multivariate Cox regression indicated higher mortality risks in Q1 and Q5 compared to Q3, with hazard ratios of 1.37 (95% CI: 1.12-1.67) and 1.35 (95% CI: 1.12-1.62), respectively.Conclusion: FPG changes before and after HF diagnosis are independent predictors of mortality, with significant changes linked to higher risks, underscoring the need for individualized glucose management in Patients with HF.","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-20"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546661","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study evaluates the impact of fasting plasma glucose (FPG) changes before and after heart failure (HF) diagnosis on all-cause mortality, offering insights into personalized HF management strategies.

Methods: A prospective cohort study based on the Kailuan study included 3533 Patients with HF after excluding those with prior HF, malignancies, or missing FPG data. FPG levels were measured before and after HF diagnosis and categorized into five groups: significant decrease (Q1), mild decrease (Q2), stable (Q3), mild increase (Q4), and significant increase (Q5). The primary endpoint was all-cause mortality, with follow-up until December 31, 2021.

Results: Over a mean follow-up of 5.63±3.80 years, 1446 deaths occurred. Kaplan-Meier analysis showed increased mortality with larger FPG changes (P<0.0001). Multivariate Cox regression indicated higher mortality risks in Q1 and Q5 compared to Q3, with hazard ratios of 1.37 (95% CI: 1.12-1.67) and 1.35 (95% CI: 1.12-1.62), respectively.

Conclusion: FPG changes before and after HF diagnosis are independent predictors of mortality, with significant changes linked to higher risks, underscoring the need for individualized glucose management in Patients with HF.

查看原文本刊更多论文

心衰诊断前后空腹血糖变化对全因死亡率的影响。

目的：本研究评估心力衰竭（HF）诊断前后空腹血糖（FPG）变化对全因死亡率的影响，为心衰（HF）个性化管理策略提供见解。方法：一项基于开滦研究的前瞻性队列研究纳入了3533例HF患者，排除了既往HF、恶性肿瘤或FPG数据缺失的患者。测定HF诊断前后FPG水平，并将FPG水平分为显著降低（Q1）、轻度降低（Q2）、稳定（Q3）、轻度升高（Q4）、显著升高（Q5）五组。主要终点为全因死亡率，随访至2021年12月31日。结果：平均随访5.63±3.80年，死亡1446例。Kaplan-Meier分析显示，FPG变化越大，死亡率越高。结论：HF诊断前后FPG变化是死亡率的独立预测指标，FPG变化与高风险相关，强调HF患者需要个体化血糖管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiology 医学-心血管系统

CiteScore

3.40

自引率

5.30%

发文量

审稿时长

1.5 months

期刊介绍： ''Cardiology'' features first reports on original clinical, preclinical and fundamental research as well as ''Novel Insights from Clinical Experience'' and topical comprehensive reviews in selected areas of cardiovascular disease. ''Editorial Comments'' provide a critical but positive evaluation of a recent article. Papers not only describe but offer critical appraisals of new developments in non-invasive and invasive diagnostic methods and in pharmacologic, nutritional and mechanical/surgical therapies. Readers are thus kept informed of current strategies in the prevention, recognition and treatment of heart disease. Special sections in a variety of subspecialty areas reinforce the journal''s value as a complete record of recent progress for all cardiologists, internists, cardiac surgeons, clinical physiologists, pharmacologists and professionals in other areas of medicine interested in current activity in cardiovascular diseases.